跳至主要内容
临床试验/NCT03680794
NCT03680794招募中不适用

sCD160 in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

CHU de Reims2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2018年6月27日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
CHU de Reims
入组人数
120
试验地点
2
主要终点
sCD160 concentration in the aqueous humor

研究概览

简要总结

CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test.

The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.

详细描述

120 patients enrolled for ophthalmic surgery (cataract or posterior segment surgery (epiretinal membrane, macular hole, vitrectomy)) will be recruited in the Department of Ophthalmology, Robert Debré Hospital, Reims, France.

Each patient will benefit a complete ophthalmologic examination, and either an aqueous sampling (cataract) or a vitreous sampling (posterior segment) along with a serum sampling at the beginning of the surgery. ELISA test will be performed on vitreous or aqueous samples in triplicates. Luminex will be performed on vitreous samples in order to determine the concentrations of several ischemia biomarkers (VEGF, PlGF, Platelet-derived growth factor (PDGF-B), SDF-1, Angpt2, InterIeukin IL-6, IL-8, CD105, Monocyte chemoattractant protein 1 (MCP-1), IL-10, interferon-inducible protein-10 ( IP-10), IL-1B and CD106, RAGE).

Primary objective is:

  • Evaluation of the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations of the vitreous or the aqueous humours.

Secondary objectives are:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

sCD160 concentration in the aqueous humor

时间窗: Day 0

ELISA test

sCD160 concentration in the vitreous humor

时间窗: Day 0

ELISA test

次要结局

  • Diabetic retinopathy severity(Day 0)
  • Vascular endothelial growth factor (VEGF)(Day 0)
  • sCD160 concentration in the serum(Day 0)
  • Stromal cell-derived factor 1 (SDF-1)(Day 0)
  • Placenta Growth Factor-1(PlGF)(Day 0)

研究者

发起方
CHU de Reims
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验